Block Grant R43AA016702

This federal Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to demonstrate the feasibility of developing a rapid point-of-care phosphatidylethanol (PEth) lateral flow immunoassay for monitoring alcohol consumption. The $399,293 award was granted to Echelon Biosciences Inc., a for-profit manufacturer of biochemical reagents and assays, to partner with an expert at Brigham Young University to...

This $235,750 Project Grant award, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to leverage existing human serum samples from longitudinal studies to characterize the effects of alcohol use disorder (AUD) and various treatments on extracellular vesicles (EVs) and their protein/lipid profiles. The goal is to assess the utility of EV-based serum diagnostics for detecting and monitoring alcohol-related white...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $499,987 Project Grant under CFDA 93.273 (Alcohol Research Programs) to CFD Research Corporation to develop a High Throughput Alcohol Screening Platform (HT-ASP) that incorporates cortical organoids. The goal is to create an automated system capable of maturing, maintaining, and assaying over 100 organoids in culture to provide a robust and genetically diverse platform for screening potential therapeutic drug candidates...

This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), aims to examine transdermal alcohol concentration (TAC) features as predictors of alcohol-related consequences and alcohol use disorders (AUD) among young adults. The $613,777 grant will fund a large-scale, 2-year longitudinal study involving 500 participants aged 19-22 who frequently engage in heavy episodic drinking. The study will utilize a...

This Project Grant award, valued at $265,510.00 and awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program, aims to evaluate the feasibility and efficacy of Trigeminal Nerve Stimulation (TNS) as a treatment for Prenatal Alcohol Exposure (PAE), a severe neurodevelopmental disorder. The proposed research comprises two phases: an initial R61 pilot study to assess the feasibility of using TNS in children...

The National Institute of Child Health and Human Development (NICHD) awarded Giner Inc., a small business research and development firm, a $624,998 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop a point-of-care testing (POCT) instrument for highly sensitive and near-real-time measurement of oxytocin levels. The project aims to create an electrochemical assay and POCT device that can accurately determine peripheral oxytocin levels...

This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, supports research to develop treatments for mental deficiencies caused by fetal exposure to alcohol. The $725,192 award to The Leland Stanford Junior University aims to characterize the dose-response relationship and maximum tolerated oral dose of the drug vinpocetine for improving neuronal plasticity in animal models of...

This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, will develop and test digital helpline intervention components aimed at reducing heavy episodic drinking (HED) during the first 3 months postpartum. The $251,309 award will be used to apply the Multiphase Optimization Strategy (MOST) framework to develop standard helpline interventions, including assessment, psychoeducation, and...

The federal Project Grant award R01AA031497, totaling $477,626.00, was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The funding supports research to investigate the role of the TET1 enzyme and sex differences in alcohol-associated liver tumorigenesis. Key objectives include determining the impact of female sex and TET1 on alcohol-induced liver fibrosis, examining the influence of TET1 and female sex hormones on...

This Project Grant award for $262,808 from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) supports research conducted by Beth Israel Deaconess Medical Center, Inc. (Bidmc) to develop and evaluate water-soluble prodrugs of the compound AKT-1005 as a potential treatment for preeclampsia. The key objectives are to synthesize, screen, and test the prodrugs for improved solubility, stability, and release of...